ClinicalTrials.gg
WithdrawnNCT01884038Updated Dec 19, 2023

Safety and Efficacy of Perioperative Remodulin® in Orthotopic Liver Transplant Recipients

A Phase 2/3 interventional study of treprostinil sodium and Placebo in Liver Transplant, sponsored by United Therapeutics. Withdrawn at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-12-19.

Sponsored by United Therapeutics · Phase 2/3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies in Reperfusion Injury with a site in United States — 5 open to participants now, 6 under way, none of them phase 3. Reperfusion Injury · United States.

Enrollment
36th of 39
0 · median 30
Started
2008
with 6 others
Phase 2/3
4 of 44
none open now
Registered
24th of 44
by date

Among the 44 studies in Reperfusion Injury with a site in United States, this one is the 36th largest by enrollment of the 39 interventional ones that give a count, is one of 7 that started in 2008, is one of 4 in phase 2/3, and was the 24th registered.

Reperfusion Injury

260 studies on the registry are indexed under Reperfusion Injury; 43 are open to participants now.

Browse Reperfusion Injury studies →

Open to participants now

5 of the 44 studies in Reperfusion Injury with a site in United States are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 28 Reperfusion Injury studies recruiting now, 16 (57%) set no upper age limit and 7 (25%) stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Reperfusion Injury with a site in United States, or all of them as a file.
02

Study summary

Patients undergoing orthotopic liver transplant will experience some degree of clinical and/or biochemical hepatic dysfunction. This early injury is known as primary graft dysfunction and varies from minor abnormalities to primary nonfunction. Prostaglandin-class drugs, including prostacyclin and its analogs, could represent an important advance toward the goal of reducing transplant related morbidity, mortality and associated costs by providing these benefits.

Read the detailed description

In vitro and in vivo research has consistently demonstrated an array of potential beneficial effects of prostanoids under both immune and non-immune circumstances relevant to liver allografts. (1-3) Recent reviews summarize the pharmacologic rationale and nonclinical and clinical experience supporting for the use of prostanoids, including prostacyclin and its analogs, in reducing early morbidity and mortality associated with liver transplantation. Prostaglandin-class drugs, including prostacyclin and its analogs, could represent an important advance toward the goal of reducing transplant related morbidity, mortality and associated costs by providing these benefits. Additionally, the reduction in serum creatinine and reduced need for post-operative dialysis observed in some studies has implications in protecting the kidneys from the nephrotoxic affects of the immunosuppressant agents, especially during the early post-operative period.

As a chemically stable analog of prostacyclin (PGI2), peri-operative intravenous administration of Remodulin is hypothesized to ameliorate or prevent reperfusion damage and thereby decrease hospitalization time and improve the clinical outcome of liver transplantation, compared to placebo control. Remodulin, as a prostanoid, is expected to facilitate restoration of the blood supply to the revascularized graft, and to provide the well-characterized protective effects of this class of compounds in liver transplant patients.

03

Conditions studied

  • Liver Transplant

Browse trials for

Keywords

  • Liver Transplant
  • Prostacyclin
  • Treprostinil sodium
  • Remodulin
  • Reperfusion Injury
  • Primary Nonfunction
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Accepted as a liver transplant candidate at the University of Pittsburgh Medical Center
  • Be receiving a cadaver donor liver transplant
  • Treated in accordance with the standard of care protocol(s) in effect for liver transplant recipients at the University of Pittsburgh Medical Center.

Exclusion criteria

Exclusion Criteria:

  • Receiving a living done liver transplant
  • Receiving a donor liver with a cold ischemia time less that 6 hours
  • Receiving a donor liver with macrosteatosis greater than 30%
  • Receiving any investigation drug with the except of alemtuzamab (Camphath)
  • Failed liver transplant in previous 180 days
  • Prior organ transplant or cell infusion
  • Undergoing multi-organ transplant
  • Pregnant or nursing female
05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Remodulin

    Remodulin initiated as a continuous IV infusion at a dose of 2.5 ng/kg/min after subjects have been assessed as hemodynamically stable in the ICU. Dose may be escalated in 1.25- to 2.5-ng/kg/min increments, up to 7.5 ng/kg/min, with a target dose of 5 ng/kg/min, based on tolerability. The dose will be maintained at the maximum tolerated dose, not to exceed 7.5 ng/kg/min for 5 days after the transplantation surgery.

    Drug: treprostinil sodium

  • Placebo comparator
    Placebo

    Matching placebo

    Drug: Placebo

Interventions

  • A single dose strength of treprostinil sodium (1.0 mg/mL) and matching placebo will be provided in 20-mL multi-dose vials. The study drug will be started after induction of anesthesia and increased incrementally to a target dose of 10 ng/kg/min during surgery and 48 hours post-operative

    Also known as: Remodulin, UT 15

  • DrugPlacebo
06

What researchers measure

Primary outcomes

  1. Duration of the initial hospitalization (days) following transplantation

    Time frame: up to 180 days

  2. Area under the curve (AUC) of serum aspartate transaminase (AST) levels.

    The difference in serum AST as measured by AUC during the first seven days post-transplant will be compared between placebo and Remodulin treatment groups. AST is a serum transaminase marker of hepatic injury, and the AUC of AST levels represents the total magnitude of injury the liver experiences against time.

    Time frame: 7 days

Secondary outcomes

  1. Serum AST and alanine transaminase (ALT ) levels after transplant (Peak and Area Under the Curve [AUC])

    Time frame: 7 days

  2. Primary allograft nonfunction defined as patient death or retransplant within 30 days due to liver failure

    Time frame: 30 days

  3. Graft survival

    Time frame: 30 days, 90 days and 180 days

  4. Subject survival at

    Time frame: Day 30, 90, and 180

  5. Post-transplant renal function

    Time frame: 30 days

  6. Duration of time spent in the intensive care unit (ICU; days) during the initial hospitalization.

    Time frame: up to 180 days

  7. Intra-operative blood product usage

    Time frame: 1 day

  8. Death from any cause

    Time frame: 180 days

  9. Total costs for initial transplant hospitalization

    Time frame: up to 180 days

07

Study locations

1 site
  • University of Pittsburgh Medical Center, Starzl Transplantation Institute
    Pittsburgh, Pennsylvania 15213, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2008, a primary completion of Jun 2010 and a completion of Jun 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 19, 2012
First posted
Jun 21, 2013
Start
Jun 2008
Primary completionEst.
Jun 2010
CompletionEst.
Jun 2010
Last update
Dec 19, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 19, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01884038
Collaborators
University of Pittsburgh Medical Center
Responsible party
Sponsor
First posted
Jun 21, 2013
Start date
Jun 2008
Primary completion
Jun 2010 (estimated)
Completion
Jun 2010 (estimated)
Last update
Dec 19, 2023

Study contacts

Amadeo Marcos, MD
principal investigator · University of Pittsburgh Medical Center
Raman Venkataramanan, Ph.D, F.C.P.
principal investigator · University of Pittsburgh Medcial Center

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jun 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Treprostinil

Start the discussion